Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Baird Maintains Outperform on Qiagen, Raises Price Target to $52

Author: Benzinga Newsdesk | August 02, 2024 10:50am
Baird analyst Catherine Schulte maintains Qiagen (NYSE:QGEN) with a Outperform and raises the price target from $49 to $52.

Posted In: QGEN

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist